Outset Medical, Inc (OM) Fair Value & Analysis
Healthcare · US · Market cap $93.6M
Outset Medical, Inc
OM · US
Fair value as of: Jun 25, 2026
From 1 valuation models · updated 4 days ago
Fair value updated Jun 25, 2026 — revised from $30.82 to $6.11 (−80.2%) since Jun 24, 2026. Share price −11.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $3.38 – $22.35 · fair‑value band $4.04 – $7.64 · the $4.63 price screens below the $6.11 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Outset Medical, Inc (OM) currently trades at $4.63, while our model-based Fair Value estimate is $6.11 — implying the stock looks roughly 32.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Outset Medical, Inc generated revenue of $118M at a net margin of -63.7%. Revenue declined 6.3% year over year. It earns a return on equity of -53.2%. Net debt stands at $66.2M. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Outset Medical, Inc reported revenue of $119M in FY2025 versus $103M in FY2021, a compound +3.9%/yr. Reported net income was −$81.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Outset Medical, Inc (OM) undervalued?
What is the fair value of OM?
What is the quality score of OM?
What is the revenue of Outset Medical, Inc (OM)?
What is the net profit margin of OM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.